- Scientists have developed a new immunotherapy approach for cholangiocarcinoma (CCA), a type of cancer that originates in the bile ducts.
- The researchers identified neoantigens, which are unique markers found on cancer cells, from patient-derived CCA cells.
- They then loaded these neoantigens onto dendritic cells (DCs), which are a type of immune cell that can present antigens to T cells.
- The neoantigen-loaded DCs were able to stimulate T cells to attack and kill the CCA cells.
- This approach has the potential to improve treatment options for CCA, which currently has limited treatment options and a poor prognosis.
Funding
- Office of the Permanent Secretary, Ministry of Higher Education, Science, Research, and Innovation (Grant no. RGNS 068-63)
- Chiang Mai University
Original Paper
Title of original paper: Enhancing cholangiocarcinoma immunotherapy with adoptive T cells targeting HLA-restricted neoantigen peptides derived from driver gene mutations
Journal: Biomedicine & Pharmacotherapy
DOI: https://doi.org/10.1016/j.biopha.2023.115827